The Latin America oncology drugs market size is estimated to reach USD 21.07 billion by 2027. In 2022, the market was sized at USD 13.10 billion, at a CAGR of 9.96% during 2022 - 2027.
Oncology helps study, diagnosis, and treatment of cancer. Cancer is a disease where abnormal cells grow uncontrollably and disrupt normal bodily functions.
Oncology drugs act against both metastatic and benign cancers which may include bone marrow cancer, lung cancer, bone cancer, skin cancer, gastrointestinal cancer, breast cancer, oral cancer, and gynecological cancer, etc. The LATAM oncology drugs market includes oral, intravenous, and parental drugs that act upon these abnormal cancerous cells and limit their growth.
The number of cancer diagnoses and deaths grows in lockstep with the need for cancer medications. As a result, this issue has a significant impact on the Latin America oncology drugs industry.
In addition, medical research is receiving increased focus to minimize cancer incidences. The sector is growing in line with rising healthcare costs in the region. The oncology industry has been bolstered by increasing cancer rates, moving the cancer therapy sector forward.
However, targeted therapy has gained in popularity as a cancer treatment in recent periods. They have a number of advantages over traditional treatment methods like chemotherapy and radiation.
An in-depth review of the market by product type elucidates the numerous types of oncology medications accessible.
On the other hand, The Latin American oncology drugs market is expected to be propelled by cutting-edge cancer treatment technologies and methodologies and increased healthcare spending in developing countries. As a result, CELGENE, Novartis, and Roche have established themselves as important players in the Latin American oncology pharmaceutical sector, with broad product portfolios and pipeline medicines garnering a significant market share.
Healthcare technology evaluation is becoming more widespread in most developed countries such as Brazil, Latin America, and Argentina.
Generic cancer pharmaceutical companies have formed strategic alliances to help them focus their efforts on developing high-efficacy generic oncology medicines. These strategic initiatives have paid off handsomely for these corporations, allowing them to preserve their market dominance in generic cancer medicines.
However, Chemotherapy drugs kill cancer cells while also destroying healthy cells in the body, causing many side effects for patients. The most common side effects include bone marrow suppression, gastrointestinal disorders, neuropathies, hair loss, fatigue, and skin illnesses. As a result, the market's growth is limited by the negative side effects of oncology treatments.
Stringent government regulations, expensive drug costs, and patient expiration are among the other factors restricting Latin American market expansion over the forecast period. Price management is a major concern in the oncology medication market, and financial risk-sharing agreements are routinely used. Pricing differences between original brands and generics are being looked into. Global trials are increasing patient recruitment to improve the local relevance of trials in Latin American regulatory processes and reduce time to market. Manufacturers should ensure that internal product development initiatives are linked from the beginning.
This research report on the Latin America oncology drugs market has been segmented and sub-segmented into the following categories:
By Drug Class Type:
By Distribution Channel:
By Route of Administration:
By Drug Classification:
The Latin America oncology drugs market is anticipated to witness a promising share during the forecast period. The regional market growth is projected to be fueled by the Proliferation of cancer rates, favorable reimbursement policies, and the presence of key market players. Breast cancer is also the most frequent type of cancer in American women. Brazil, Mexico, and Argentina play a significant role in the LATAM oncology drugs market. Even Peru and Chile are some countries that have a significant role in dealing with oncology drug development and providing better infrastructure. in some countries like Brazil, Mexico, and Argentina, prostate cancer is the most common in the regions. Cervical and liver cancers, on the other hand, are more common in other areas.
Brazil dominates the Latin America oncology drugs market during the forecast period, and it is likely to continue its growth in the coming years. The market growth is fueled by a significant increase in the healthcare infrastructure, healthcare expenditure, and growing awareness about oncology drugs. In addition, the government established healthcare investments, and several multi-national organizations are funding cancer medications.
On the other hand, Mexico is more likely to witness a promising share in the Latin America oncology drugs market in the coming years. Lung cancer is the most prevalent sort of drug use in the country. Mexico plays a significant role in the procurement of various anticancer prescription treatments in Latin America. Better cancer pharmaceutical treatments are being introduced to the market.
KEY MARKET PLAYERS:
F. Hoffmann-La Roche Ltd, Genentech, Inc., Novartis AG, Pfizer Inc., Bristol-Myers Squibb Company, GlaxoSmithKline plc, Eli Lilly and Company, AstraZeneca, Sanofi, and Bayer AG are some of the notable companies in the Latin America oncology drugs market.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: firstname.lastname@example.org